What is Adaptive Biotechnologies Corp Annual Revenue?

Adaptive Biotechnologies Corp Annual Revenue rose 5.1%, in the last year to $178.96 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Adaptive Biotechnologies Corp Annual Net Profit?

Adaptive Biotechnologies Corp Annual Net Profit rose 29.19% in the last year to $159.49 M. Its sector's average net profit growth for the last fiscal year was -32.48%.

What is Adaptive Biotechnologies Corp Price to Earning Ratio?

Adaptive Biotechnologies Corp Price to Earning Ratio is -6.88, which is negative.

What is Adaptive Biotechnologies Corp Stock Price?

Adaptive Biotechnologies Corp Stock Price rose 194.02% and outperformed its sector by 183.68% in the past year.

What is Adaptive Biotechnologies Corp Quarterly Revenue?

Adaptive Biotechnologies Corp Quarterly Revenue rose 3.66% YoY to $47.46 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Adaptive Biotechnologies Corp Quarterly Net profit?

Adaptive Biotechnologies Corp Quarterly Net profit rose 51.48% YoY to $33.69 M. Its sector's average net profit growth YoY for the quarter was -42%.

What is Adaptive Biotechnologies Corp Debt to Equity Ratio?

Adaptive Biotechnologies Corp Debt to Equity Ratio of 0.44 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Adaptive Biotechnologies Corp Return on Equity(ROE)?

Adaptive Biotechnologies Corp Return on Equity(ROE) for the last financial year was -62.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Adaptive Biotechnologies Corp Mutual Fund Holding?

Adaptive Biotechnologies Corp Mutual Fund Holding increased by 3.47% in the last quarter to 58.48.

What is Adaptive Biotechnologies Corp Promoter Share Holding?

Adaptive Biotechnologies Corp Promoter Share Holding increased by 0.88% in the most recent quarter to 5.3%.

What is Adaptive Biotechnologies Corp Interest Coverage Ratio?

Adaptive Biotechnologies Corp Interest Coverage Ratio is -12.78, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Adaptive Biotechnologies Corp Institutional Holding?

Adaptive Biotechnologies Corp Institutional Holding increased by 0.09% in the last quarter to 97.21.

How is the Adaptive Biotechnologies Corp today?

The Adaptive Biotechnologies Corp today is trading in the green, up by 5.28% at 7.38.

How has Adaptive Biotechnologies Corp performed historically?

The Adaptive Biotechnologies Corp is currently trading up 5.28% on an intraday basis in the past week the index fell -4.65%. The index has been down -7.87% in the past quarter and rose 194.02% in the past year. You can view this in the overview section.

Adaptive Biotechnologies Corp XNAS: ADPT

Adaptive Biotechnologies Corp Live Share Price Today, Share Analysis and Chart

Name: Adaptive Biotechnologies Corp: Is Infosys Ltd. worth buying?
Item: Adaptive Biotechnologies Corp
Rating: 1.4750695
Author: Trendlyne DVM scores

Momentum Trap

Download real time

7.38 0.37 (5.28%)

201.22% Gain from 52W Low

1.9M XNAS Volume

XNAS 23 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Adaptive Biotechnologies Corp is on 01 May 2025 for the purpose of Adaptive Biotechnologies Corp First Quarter Earnings Conference Call for 2025 See details

Adaptive Biotechnologies Corp Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	1,096.5
PE TTM Negative PE TTM Unavailable in chosen country	-6.9
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.2
Price to Book High in industry Unavailable in chosen country	5.4
Institutional holding current Qtr % High in industry Unavailable in chosen country	97.2
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	3.7
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	5.1
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	51.5
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	29.2
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-71.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-86.8
Piotroski Score High in industry Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-8.1
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-62.4
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-26.6

All financials are in USD Million and price data in USD

Low Financial Strength

27.8 / 100

Expensive Valuation

11.0 / 100

Technically Neutral

51.5 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 32%

7 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Adaptive Biotechnologies Corp Stock Price Analysis

Day Price Range 5.3% 1 Day return Unavailable in chosen country	7.4 (LTP) 7.37.9 LowHigh
Week Price Range -4.6% 1 Week return Unavailable in chosen country	7.4 (LTP) 6.87.9 LowHigh
Month Price Range -12.1% 1 Month return Unavailable in chosen country	7.4 (LTP) 6.79 LowHigh
52 Week Price Range 194.0% 1 Year return Unavailable in chosen country	7.4 (LTP) 2.49 LowHigh

View full Share Price History

Adaptive Biotechnologies Corp Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Adaptive Biotechnologies Corp's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-1.1

Avg. Estimate

-0.9

Low Estimate

-1

High Estimate

-0.8

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 14.8% in FY25

Consensus Recommendation

8 ANALYST Recommendations

BUY

The consensus recommendation from 8 analysts for Adaptive Biotechnologies Corp is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Adaptive Biotechnologies Corp Stock Analysis

Adaptive Biotechnologies Corp stock analysis with key metrics, changes, and trends.

Adaptive Biotechnologies Corp Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$178.96 M	5.1%	positive	Annual Revenue rose 5.1%, in the last year to $178.96 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$159.49 M	29.19%	positive	Annual Net Profit rose 29.19% in the last year to $159.49 M. Its sector's average net profit growth for the last fiscal year was -32.48%.
Price to Earning Ratio	-6.88	-	negative	Price to Earning Ratio is -6.88, which is negative.
Stock Price	$7.38	194.02%	positive	Stock Price rose 194.02% and outperformed its sector by 183.68% in the past year.
Quarterly Revenue	$47.46 M	3.66%	positive	Quarterly Revenue rose 3.66% YoY to $47.46 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$33.69 M	51.48%	positive	Quarterly Net profit rose 51.48% YoY to $33.69 M. Its sector's average net profit growth YoY for the quarter was -42%.
Debt to Equity Ratio	0.44	-	positive	Debt to Equity Ratio of 0.44 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-62.41 %	-62.41%	negative	Return on Equity(ROE) for the last financial year was -62.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	58.48 %	3.47%	positive	Mutual Fund Holding increased by 3.47% in the last quarter to 58.48.
Promoter Share Holding	5.30 %	0.88%	positive	Promoter Share Holding increased by 0.88% in the most recent quarter to 5.3%.
Interest Coverage Ratio	-12.78	-	negative	Interest Coverage Ratio is -12.78, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	97.21 %	0.09%	positive	Institutional Holding increased by 0.09% in the last quarter to 97.21.

VIEW LESS

Loading data..

Adaptive Biotechnologies Corp - Company Profile

What does Adaptive Biotechnologies Corp do?

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Gross Remuneration

2024

Gross Remuneration

Year

Adaptive Biotechnologies Corp Live Share Price Today, Share Analysis and Chart

201.22% Gain from 52W Low

Adaptive Biotechnologies Corp Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Adaptive Biotechnologies Corp Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Adaptive Biotechnologies Corp Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Adaptive Biotechnologies Corp's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 14.8% in FY25

Consensus Recommendation

The consensus recommendation from 8 analysts for Adaptive Biotechnologies Corp is BUY

Adaptive Biotechnologies Corp Stock Analysis

Adaptive Biotechnologies Corp stock analysis with key metrics, changes, and trends.

Annual Revenue rose 5.1%, in the last year to $178.96 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 29.19% in the last year to $159.49 M. Its sector's average net profit growth for the last fiscal year was -32.48%.

Price to Earning Ratio is -6.88, which is negative.

Stock Price rose 194.02% and outperformed its sector by 183.68% in the past year.

Quarterly Revenue rose 3.66% YoY to $47.46 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit rose 51.48% YoY to $33.69 M. Its sector's average net profit growth YoY for the quarter was -42%.

Debt to Equity Ratio of 0.44 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -62.41%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 3.47% in the last quarter to 58.48.

Promoter Share Holding increased by 0.88% in the most recent quarter to 5.3%.

Interest Coverage Ratio is -12.78, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.09% in the last quarter to 97.21.

Adaptive Biotechnologies Corp - Company Profile

What does Adaptive Biotechnologies Corp do?

Adaptive Biotechnologies Corp Management structure

Mr. Kyle Piskel

Chief Financial Officer and Principal Accounting Officer

Mr. Tycho Peterson

Chief Financial Officer

Mr. Chad M. Robins

Chairman of the Board and Chief Executive Officer

Adaptive Biotechnologies Corp Board of directors

Dr. Michael J. Pellini,M.D.

Independent Director

Mr. Peter M. Neupert

Lead Independent Director

Dr. Robert M. Hershberg, M.D.,PhD

Independent Director

Ms. Michelle Griffin